74927-72-3 | (R)-(-)-N-(3,5-Dinitrobenzoyl)-alpha-phenylglycine

Packsize	Purity	Availability	Price	Discounted Price
1g	98%	in stock	$19.00	$13.00
5g	98%	in stock	$25.00	$17.00
25g	98%	in stock	$41.00	$29.00
100g	98%	in stock	$106.00	$75.00

Description

• Catalog Number: AB55445
• Chemical Name: (R)-(-)-N-(3,5-Dinitrobenzoyl)-alpha-phenylglycine
• CAS Number: 74927-72-3
• Molecular Formula: C15H11N3O7
• Molecular Weight: 345.26374
• MDL Number: MFCD00010134
• SMILES: OC(=O)[C@H](c1ccccc1)NC(=O)c1cc(cc(c1)[N+](=O)[O-])[N+](=O)[O-]

Computed Properties

• Complexity: 514
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 25
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 4
• XLogP3: 2.1

Upstream Synthesis Route

The (R)-(-)-N-(3,5-Dinitrobenzoyl)-alpha-phenylglycine is a versatile compound commonly utilized in chemical synthesis. This compound is specifically valuable in the field of asymmetric synthesis, where the control of stereochemistry is essential to produce chiral molecules with high enantiomeric purity. By incorporating (R)-(-)-N-(3,5-Dinitrobenzoyl)-alpha-phenylglycine into synthetic pathways, chemists can efficiently access enantiomerically enriched compounds that are crucial for pharmaceutical, agrochemical, and materials science applications. This compound serves as a key building block in the construction of complex molecules with precise stereochemical arrangements, making it a valuable tool for researchers and synthetic chemists aiming to develop new chemical entities with enhanced properties and functionalities.

Literature

• Solvation of phenylglycine- and leucine-derived chiral stationary phases: molecular dynamics simulation study.

  The journal of physical chemistry. B 20081016

• A screening method for chiral selectors that does not require covalent attachment.

  Journal of the American Chemical Society 20060222

• Capillary electrophoresis with (R)-(--)-N-(3,5-dinitrobenzoyl)-alpha-phenylglycine as chiral selector for separation of albendazole sulfoxide enantiomers and their analysis in human plasma.

  Journal of pharmaceutical and biomedical analysis 20020115

• QSAR of matrix metalloproteinase inhibitor N-[(substituted phenyl)sulfonyl]-N-4-nitrobenzylglycine hydroxamates using LFER model.

  Drug design and discovery 20010101